William H. Frishman

Menopausal Hormone Therapy and Cardiovascular Risk: Current Evidence and Treatment Recommendations

In 2025, the US Food and Drug Administration (FDA) removed its prior class-wide boxed warnings for menopausal hormone therapy (MHT), paving the way for increased clinical use. Menopause accelerates cardiovascular risk independently of chronological aging, manifesting as a 7.5% in...